Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (NYSE:OCS) disclosed two notifications dated Oct 14, 2025 showing a director exercised vested stock options and then sold the resulting ordinary shares.

The filings indicate the transactions were executed under a 10b5-1 trading plan in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934. Attachments reference notifications for C. Ackermann covering the option exercise and subsequent share sale.

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The attached two notifications relate to the exercise of vested stock options to purchase ordinary shares previously granted to a director of the Company, and the subsequent sale of those ordinary shares. These transactions were entered into pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.

Attachments

• pdmr-notification-C-Ackermann-option exercise-oct 2025
• pdmr-notification-C-Ackermann-sale of shares-oct 2025

FAQ

What did Oculis (OCS) disclose on October 14, 2025 regarding insider transactions?

Oculis disclosed that a director exercised vested stock options and subsequently sold the resulting ordinary shares, with filings dated October 14, 2025.

Were the Oculis (OCS) insider trades executed under a 10b5-1 plan?

Yes. The notifications state the transactions were entered pursuant to a 10b5-1 trading plan under Rule 10b5-1(c)(1).

Which director is named in the Oculis (OCS) transaction attachments dated Oct 2025?

The attached notification filenames reference C. Ackermann as the director tied to the option exercise and share sale.

Do the Oculis (OCS) disclosures on Oct 14, 2025 report any company financial impact?

No financial figures or revenue impacts are reported; the filings describe only the option exercise and sale transactions.

How can investors view the Oct 14, 2025 Oculis (OCS) notifications of transactions by a director?

Investors can review the submitted PDmR/insider transaction notifications attached with the disclosure, which list the option exercise and sale details.

Does the Oct 14, 2025 Oculis (OCS) disclosure indicate any regulatory violation?

No. The disclosure states the trades were made pursuant to a compliant 10b5-1 trading plan and does not allege any wrongdoing.